in trading halt, page-64

and lets not forget.....

'To date no patients dosed with ATL1103 have withdrawn from the study nor have any serious adverse
events, believed to be treatment-related, been reported. So far, both doses appear to be well tolerated.
The positive safety profile to date suggests the drug may be tolerated at higher levels than 400 mg
per week and so the Company is considering the prospect of conducting a small add-on study to
support the use of a higher dose in Phase III trials for dose escalation in patients with more active
disease.'

Theres upside left in this treatment it would seem. And no safety concerns, which was my biggest concern

merry xmas to all the hard working folk at ANP.